A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium

William Checkley, A. Clinton White, Devan Jaganath, Michael J. Arrowood, Rachel M. Chalmers, Xian Ming Chen, Ronald Fayer, Jeffrey K. Griffiths, Richard L. Guerrant, Lizbeth Hedstrom, Christopher D. Huston, Karen L. Kotloff, Gagandeep Kang, Jan R. Mead, Mark Miller, William A. Petri, Jeffrey W. Priest, David S. Roos, Boris Striepen, R. C Andrew Thompson & 5 others Honorine D. Ward, Wesley A. Van Voorhis, Lihua Xiao, Guan Zhu, Eric R. Houpt

Research output: Contribution to journalArticle

267 Citations (Scopus)

Abstract

Cryptosporidium spp are well recognised as causes of diarrhoeal disease during waterborne epidemics and in immunocompromised hosts. Studies have also drawn attention to an underestimated global burden and suggest major gaps in optimum diagnosis, treatment, and immunisation. Cryptosporidiosis is increasingly identified as an important cause of morbidity and mortality worldwide. Studies in low-resource settings and high-income countries have confirmed the importance of cryptosporidium as a cause of diarrhoea and childhood malnutrition. Diagnostic tests for cryptosporidium infection are suboptimum, necessitating specialised tests that are often insensitive. Antigen-detection and PCR improve sensitivity, and multiplexed antigen detection and molecular assays are underused. Therapy has some effect in healthy hosts and no proven efficacy in patients with AIDS. Use of cryptosporidium genomes has helped to identify promising therapeutic targets, and drugs are in development, but methods to assess the efficacy in vitro and in animals are not well standardised. Partial immunity after exposure suggests the potential for successful vaccines, and several are in development; however, surrogates of protection are not well defined. Improved methods for propagation and genetic manipulation of the organism would be significant advances.

Original languageEnglish (US)
Pages (from-to)85-94
Number of pages10
JournalThe Lancet Infectious Diseases
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Cryptosporidium
Vaccines
Cryptosporidiosis
Antigens
Immunocompromised Host
Therapeutics
Routine Diagnostic Tests
Malnutrition
Diarrhea
Immunity
Immunization
Acquired Immunodeficiency Syndrome
Genome
Morbidity
Polymerase Chain Reaction
Mortality
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. / Checkley, William; White, A. Clinton; Jaganath, Devan; Arrowood, Michael J.; Chalmers, Rachel M.; Chen, Xian Ming; Fayer, Ronald; Griffiths, Jeffrey K.; Guerrant, Richard L.; Hedstrom, Lizbeth; Huston, Christopher D.; Kotloff, Karen L.; Kang, Gagandeep; Mead, Jan R.; Miller, Mark; Petri, William A.; Priest, Jeffrey W.; Roos, David S.; Striepen, Boris; Thompson, R. C Andrew; Ward, Honorine D.; Van Voorhis, Wesley A.; Xiao, Lihua; Zhu, Guan; Houpt, Eric R.

In: The Lancet Infectious Diseases, Vol. 15, No. 1, 01.01.2015, p. 85-94.

Research output: Contribution to journalArticle

Checkley, W, White, AC, Jaganath, D, Arrowood, MJ, Chalmers, RM, Chen, XM, Fayer, R, Griffiths, JK, Guerrant, RL, Hedstrom, L, Huston, CD, Kotloff, KL, Kang, G, Mead, JR, Miller, M, Petri, WA, Priest, JW, Roos, DS, Striepen, B, Thompson, RCA, Ward, HD, Van Voorhis, WA, Xiao, L, Zhu, G & Houpt, ER 2015, 'A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium', The Lancet Infectious Diseases, vol. 15, no. 1, pp. 85-94. https://doi.org/10.1016/S1473-3099(14)70772-8
Checkley, William ; White, A. Clinton ; Jaganath, Devan ; Arrowood, Michael J. ; Chalmers, Rachel M. ; Chen, Xian Ming ; Fayer, Ronald ; Griffiths, Jeffrey K. ; Guerrant, Richard L. ; Hedstrom, Lizbeth ; Huston, Christopher D. ; Kotloff, Karen L. ; Kang, Gagandeep ; Mead, Jan R. ; Miller, Mark ; Petri, William A. ; Priest, Jeffrey W. ; Roos, David S. ; Striepen, Boris ; Thompson, R. C Andrew ; Ward, Honorine D. ; Van Voorhis, Wesley A. ; Xiao, Lihua ; Zhu, Guan ; Houpt, Eric R. / A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. In: The Lancet Infectious Diseases. 2015 ; Vol. 15, No. 1. pp. 85-94.
@article{9472457e9a464d2ca73ee0fac0277de5,
title = "A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium",
abstract = "Cryptosporidium spp are well recognised as causes of diarrhoeal disease during waterborne epidemics and in immunocompromised hosts. Studies have also drawn attention to an underestimated global burden and suggest major gaps in optimum diagnosis, treatment, and immunisation. Cryptosporidiosis is increasingly identified as an important cause of morbidity and mortality worldwide. Studies in low-resource settings and high-income countries have confirmed the importance of cryptosporidium as a cause of diarrhoea and childhood malnutrition. Diagnostic tests for cryptosporidium infection are suboptimum, necessitating specialised tests that are often insensitive. Antigen-detection and PCR improve sensitivity, and multiplexed antigen detection and molecular assays are underused. Therapy has some effect in healthy hosts and no proven efficacy in patients with AIDS. Use of cryptosporidium genomes has helped to identify promising therapeutic targets, and drugs are in development, but methods to assess the efficacy in vitro and in animals are not well standardised. Partial immunity after exposure suggests the potential for successful vaccines, and several are in development; however, surrogates of protection are not well defined. Improved methods for propagation and genetic manipulation of the organism would be significant advances.",
author = "William Checkley and White, {A. Clinton} and Devan Jaganath and Arrowood, {Michael J.} and Chalmers, {Rachel M.} and Chen, {Xian Ming} and Ronald Fayer and Griffiths, {Jeffrey K.} and Guerrant, {Richard L.} and Lizbeth Hedstrom and Huston, {Christopher D.} and Kotloff, {Karen L.} and Gagandeep Kang and Mead, {Jan R.} and Mark Miller and Petri, {William A.} and Priest, {Jeffrey W.} and Roos, {David S.} and Boris Striepen and Thompson, {R. C Andrew} and Ward, {Honorine D.} and {Van Voorhis}, {Wesley A.} and Lihua Xiao and Guan Zhu and Houpt, {Eric R.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/S1473-3099(14)70772-8",
language = "English (US)",
volume = "15",
pages = "85--94",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium

AU - Checkley, William

AU - White, A. Clinton

AU - Jaganath, Devan

AU - Arrowood, Michael J.

AU - Chalmers, Rachel M.

AU - Chen, Xian Ming

AU - Fayer, Ronald

AU - Griffiths, Jeffrey K.

AU - Guerrant, Richard L.

AU - Hedstrom, Lizbeth

AU - Huston, Christopher D.

AU - Kotloff, Karen L.

AU - Kang, Gagandeep

AU - Mead, Jan R.

AU - Miller, Mark

AU - Petri, William A.

AU - Priest, Jeffrey W.

AU - Roos, David S.

AU - Striepen, Boris

AU - Thompson, R. C Andrew

AU - Ward, Honorine D.

AU - Van Voorhis, Wesley A.

AU - Xiao, Lihua

AU - Zhu, Guan

AU - Houpt, Eric R.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Cryptosporidium spp are well recognised as causes of diarrhoeal disease during waterborne epidemics and in immunocompromised hosts. Studies have also drawn attention to an underestimated global burden and suggest major gaps in optimum diagnosis, treatment, and immunisation. Cryptosporidiosis is increasingly identified as an important cause of morbidity and mortality worldwide. Studies in low-resource settings and high-income countries have confirmed the importance of cryptosporidium as a cause of diarrhoea and childhood malnutrition. Diagnostic tests for cryptosporidium infection are suboptimum, necessitating specialised tests that are often insensitive. Antigen-detection and PCR improve sensitivity, and multiplexed antigen detection and molecular assays are underused. Therapy has some effect in healthy hosts and no proven efficacy in patients with AIDS. Use of cryptosporidium genomes has helped to identify promising therapeutic targets, and drugs are in development, but methods to assess the efficacy in vitro and in animals are not well standardised. Partial immunity after exposure suggests the potential for successful vaccines, and several are in development; however, surrogates of protection are not well defined. Improved methods for propagation and genetic manipulation of the organism would be significant advances.

AB - Cryptosporidium spp are well recognised as causes of diarrhoeal disease during waterborne epidemics and in immunocompromised hosts. Studies have also drawn attention to an underestimated global burden and suggest major gaps in optimum diagnosis, treatment, and immunisation. Cryptosporidiosis is increasingly identified as an important cause of morbidity and mortality worldwide. Studies in low-resource settings and high-income countries have confirmed the importance of cryptosporidium as a cause of diarrhoea and childhood malnutrition. Diagnostic tests for cryptosporidium infection are suboptimum, necessitating specialised tests that are often insensitive. Antigen-detection and PCR improve sensitivity, and multiplexed antigen detection and molecular assays are underused. Therapy has some effect in healthy hosts and no proven efficacy in patients with AIDS. Use of cryptosporidium genomes has helped to identify promising therapeutic targets, and drugs are in development, but methods to assess the efficacy in vitro and in animals are not well standardised. Partial immunity after exposure suggests the potential for successful vaccines, and several are in development; however, surrogates of protection are not well defined. Improved methods for propagation and genetic manipulation of the organism would be significant advances.

UR - http://www.scopus.com/inward/record.url?scp=84918574823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918574823&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(14)70772-8

DO - 10.1016/S1473-3099(14)70772-8

M3 - Article

VL - 15

SP - 85

EP - 94

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

IS - 1

ER -